Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010The Lancet (British edition), 2013-11, Vol.382 (9904), p.1575-1586 [Peer Reviewed Journal]Elsevier Ltd ;2013 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Nov 9, 2013 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)61611-6 ;PMID: 23993280 ;CODEN: LANCAOFull text available |
|
2 |
Material Type: Article
|
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet (British edition), 2012-06, Vol.379 (9834), p.2352-2363 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 23-Jun 29, 2012 ;2012 Elsevier Ltd. All rights reserved. 2012 Elsevier Ltd ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)60768-5 ;PMID: 22632908 ;CODEN: LANCAOFull text available |
|
3 |
Material Type: Article
|
Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological studyThe Lancet infectious diseases, 2019-11, Vol.19 (11), p.1209-1218 [Peer Reviewed Journal]2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(19)30446-3 ;PMID: 31519541Full text available |
|
4 |
Material Type: Article
|
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational journal of cancer, 2019-04, Vol.144 (8), p.1941 [Peer Reviewed Journal]2018 UICC. ;EISSN: 1097-0215 ;DOI: 10.1002/ijc.31937 ;PMID: 30350310Digital Resources/Online E-Resources |
|
5 |
Material Type: Article
|
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesThe Lancet (British edition), 2013-05, Vol.381 (9880), p.1817-1826 [Peer Reviewed Journal]Elsevier Ltd ;2013 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited May 25, 2013 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)60313-X ;PMID: 23615461 ;CODEN: LANCAOFull text available |
|
6 |
Material Type: Article
|
What advanced cancer patients with limited treatment options know about clinical research: a qualitative studySupportive care in cancer, 2017-10, Vol.25 (10), p.3235-3242 [Peer Reviewed Journal]Springer-Verlag Berlin Heidelberg 2017 ;COPYRIGHT 2017 Springer ;Supportive Care in Cancer is a copyright of Springer, 2017. ;ISSN: 0941-4355 ;EISSN: 1433-7339 ;DOI: 10.1007/s00520-017-3734-4 ;PMID: 28488050Full text available |
|
7 |
Material Type: Article
|
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2020-10, Vol.396 (10259), p.1345-1352 [Peer Reviewed Journal]2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at http://creativecommons.org/licenses/by/4.0 ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)32013-4 ;PMID: 33031764Digital Resources/Online E-Resources |
|
8 |
Material Type: Article
|
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapyJournal for immunotherapy of cancer, 2021-04, Vol.9 (4), p.e002071 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. 2021 ;ISSN: 2051-1426 ;EISSN: 2051-1426 ;DOI: 10.1136/jitc-2020-002071 ;PMID: 33858848Full text available |
|
9 |
Material Type: Article
|
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trialThe lancet oncology, 2020-04, Vol.21 (4), p.508-518 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30074-7 ;PMID: 32135080Full text available |
|
10 |
Material Type: Article
|
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet (British edition), 2021-05, Vol.397 (10285), p.1637-1645 [Peer Reviewed Journal]2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Published by Elsevier Ltd. All rights reserved. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00676-0 ;PMID: 33933206Full text available |
|
11 |
Material Type: Article
|
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsThe lancet oncology, 2020-04, Vol.21 (4), p.531-540 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30856-3 ;PMID: 32105622Full text available |
|
12 |
Material Type: Article
|
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort studyThe Lancet infectious diseases, 2022-01, Vol.22 (1), p.35-42 [Peer Reviewed Journal]2022 ;Crown copyright © 2022 Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;Copyright Elsevier Limited Jan 2022 ;Crown Copyright © 2021 Published by Elsevier Ltd. 2022 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(21)00475-8 ;PMID: 34461056Full text available |
|
13 |
Material Type: Article
|
Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)The Lancet (British edition), 2015-03, Vol.385 (9972), p.977-1010 [Peer Reviewed Journal]Allemani et al. Open Access article distributed under the terms of CC BY ;2015 Allemani et al. Open Access article distributed under the terms of CC BY ;Copyright © 2015 Allemani et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 14, 2015 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)62038-9 ;PMID: 25467588 ;CODEN: LANCAOFull text available |
|
14 |
Material Type: Article
|
Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance studyJournal of cardiovascular magnetic resonance, 2014-10, Vol.16 (1), p.69-69, Article 69 [Peer Reviewed Journal]COPYRIGHT 2014 BioMed Central Ltd. ;COPYRIGHT 2014 BioMed Central Ltd. ;2014 Dabir et al.; licensee BioMed Central Ltd. ;Dabir et al.; licensee BioMed Central Ltd. 2014 ;ISSN: 1532-429X ;ISSN: 1097-6647 ;EISSN: 1532-429X ;DOI: 10.1186/s12968-014-0069-x ;PMID: 25384607Full text available |
|
15 |
Material Type: Article
|
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trialThe Lancet (British edition), 2020-05, Vol.395 (10237), p.1613-1626 [Peer Reviewed Journal]2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30932-6 ;PMID: 32580883Full text available |
|
16 |
Material Type: Article
|
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort studyThe Lancet (British edition), 2021-05, Vol.397 (10285), p.1646-1657 [Peer Reviewed Journal]2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00677-2 ;PMID: 33901420Full text available |
|
17 |
Material Type: Article
|
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trialThe Lancet (British edition), 2021-05, Vol.397 (10289), p.2049-2059 [Peer Reviewed Journal]2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00897-7 ;PMID: 34000257Full text available |
|
18 |
Material Type: Article
|
Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensembleThe Lancet (British edition), 2017-04, Vol.389 (10076), p.1323-1335 [Peer Reviewed Journal]The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license ;2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license ;Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved. ;Copyright Elsevier Limited Apr 1, 2017 ;2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)32381-9 ;PMID: 28236464Full text available |
|
19 |
Material Type: Article
|
Regulatory T Cells Exhibit Distinct Features in Human Breast CancerImmunity (Cambridge, Mass.), 2016-11, Vol.45 (5), p.1122-1134 [Peer Reviewed Journal]2016 Elsevier Inc. ;Copyright © 2016 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Nov 15, 2016 ;ISSN: 1074-7613 ;EISSN: 1097-4180 ;DOI: 10.1016/j.immuni.2016.10.032 ;PMID: 27851913Full text available |
|
20 |
Material Type: Article
|
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19New England Journal of Medicine, 2021-09, Vol.385 (13), p.1184-1195 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2109682 ;PMID: 34347950Digital Resources/Online E-Resources |